期刊文献+

鞘氨醇激酶1抑制剂和5-FU联合应用对体外胃癌细胞增殖与凋亡的影响

Effects of sphingosine kinase 1 inhibitors combined with 5-FU on proliferation and apoptosis of gastric cancer cells in vitro
原文传递
导出
摘要 目的观察鞘氨醇激酶1(SphK1)抑制剂二甲基鞘氨醇(DMS)与化疗药物5-氟尿嘧啶(5-FU)联合应用对体外胃癌细胞SGC7901增殖与凋亡的影响。方法体外培养人胃癌细胞株SGC7901,分别单用不同浓度5-FU(1、5、25μg/ml)或5-FU与DMS(1μmol/L)联合应用。MTT比色法检测各组细胞生长抑制率,光镜下观察细胞形态变化,流式细胞术检测各组细胞凋亡率。通过SAS软件进行反应曲面分析,分析两药之间的关系。结果不同浓度的5-FU单用组及联用DMS组的抑制率差异有统计学意义(P<0.05),联用组抑制率均高于单用组,两者具有协同作用。单用DMS组及5-FU组的胃癌细胞凋亡率较空白对照组明显增高,联用组凋亡率较单用组明显增加(P<0.05)。结论 DMS可抑制SGC7901细胞的增殖;DMS和5-FU联用显示了较好的协同作用,提示抑制SphK1活性能够提高胃癌细胞对于化疗药物的敏感性。 Objective To investigate the effects of N,N-Dimethylsphingosine(DMS) combined with 5-fluorouracil(5-FU) on the proliferation and apoptosis of gastric cancer cells(SGC7901) in vitro.Methods The SGC7901 cells were incubated in vitro with different concentrations of 5-FU(1,5 μg/ml and 25 μg/ml) alone or combined use of different concentrations of 5-FU and DMS(1 μmol/L).The growth and survival of SGC7901 cells were determined by MTT assay.Apoptosis was measured using flow cytometry.By the response surface analysis of those inhibition rates,the interactive relationships between the combined drugs were evaluated on the basis of positive/negative value of the cross product coefficient in the response surface equation.Results The inhibition rate of SGC7901 cells by DMS(1 μmol/L) for 24 hours was(10.23±0.74)%.The inhibition rates of SGC7901 cells by 5-FU 1,5 μg/ml and 25 μg/ml were(9.95±3.24)%,(21.4±2.19)% and(45.49±3.60)%,respectively,which were lower than(16.76±0.41)%,(27.28±0.29)% and(52.56±0.36)% when DMS was combined with different concentrations of 5-FU(P〈0.05).The apoptosis rates of SGC7901 cells were(7.56±1.47)% and(9.08±2.04)% when treated with DMS 1 μmol/L and 5-FU 1 μg/ml,respectively,which were more than(1.48±0.39)% in control group.When 5-FU was combined with DMS,the apoptosis rate was(17.68±3.66)%,which was more than that of each of single 5-FU groups(P〈0.05).Conclusion DMS is able to suppress SGC7901 cells in vitro and the synergetic effect became evident when it is used in combination with 5-FU,suggesting that sphingosine kinase 1(SphK1) inhibitors could be used as the synergetic agents in chemotherapy.
出处 《江苏医药》 CAS CSCD 北大核心 2012年第7期760-762,共3页 Jiangsu Medical Journal
关键词 胃癌 二甲基鞘氨醇 5-氟尿嘧啶 鞘氨醇激酶1 Gastric cancer N, N-Dimethylsphingosine 5-Fluorouracil Sphingosine kinase 1
  • 相关文献

参考文献13

  • 1Cuvillier O,Ader I,Bouquerel P,et al.Activation of sphingo-sine kinase-1in cancer:implications for therapeutic targeting[J].Curr Mol Pharmacol,2010,3(2):53-65.
  • 2Sauer L,Nunes J,Salunkhe V,et al.Sphingosine kinase 1inhibition sensitizes hormone-resistant prostate cancer todocetaxel[J].Int J Cancer,2009,125(11):2728-2736.
  • 3Morales A,Paris R,Villanueva A,et al.Pharmacologicalinhibition or small interfering RNA targeting acid ceramidasesensitizes hepatoma cells to chemotherapy and reduces tumorgrowth in vivo[J].Oncogene,2007,26(6):905-916.
  • 4Guillermet-Guibert J,Davenne L,Pchejetski D,et al.Targe-ting the sphingolipid metabolism to defeat pancreatic cancercell resistance to the chemotherapeutic gemcitabine drug[J].Mol Cancer Ther,2009,8(4):809-820.
  • 5朱风尚,陈锡美,王毅军,张霞,冯久贤.特异性环氧合酶抑制剂和抗癌药联用对胃癌细胞增殖的影响[J].中华肿瘤杂志,2007,29(3):186-188. 被引量:15
  • 6刘立新,张智.希罗达联合周剂量奥沙利铂治疗老年晚期胃癌的疗效[J].江苏医药,2010,36(5):536-538. 被引量:2
  • 7Betito S,Cuvillier O.Regulation by sphingosine 1-phosphateof Bax and Bad activities during apoptosis in a MEK-dependent manner[J].Biochem Biophys Res Commun,2006,340(4):1273-1277.
  • 8Pchejetski D,Golzio M,Bonhoure E,et al.Sphingosinekinase-1as a chemotherapy sensor in prostate adenocarcinomacell and mouse models[J].Cancer Res,2005,65(24):11667-11675.
  • 9Igarashi Y,Hakomori S.Enzymatic synthesis of N,N-dime-thyl-sphingosine:demonstration of the sphingosine:N-meth-yltransferase in mouse brain[J].Biochem Biophys ResCommun,1989,164(3):1411-1416.
  • 10Edsall LC,Van Brocklyn JR,Cuvillier O,et al.N,N-Dimeth-ylsphingosine is a potent competitive inhibitor of sphingosinekinase but not of protein kinase C:modulation of cellularlevels of sphingosine 1-phosphate and ceramide[J].Biochemistry,1998,37(37):12892-12898.

二级参考文献14

  • 1刘红英,张琍.尼美舒利增强丝裂霉素抑制体外培养人胃癌细胞的细胞增殖及诱导凋亡的实验研究[J].中华消化内镜杂志,2004,21(4):267-269. 被引量:3
  • 2朱风尚,陈锡美,朱国英,王志荣,王毅军,张霞.特异性环氧合酶抑制剂对胃癌细胞BGC-823生长的影响[J].同济大学学报(医学版),2005,26(1):21-25. 被引量:4
  • 3樊晓明,郑发寿,刘红燕,马元华,王振宇.环氧合酶-2特异抑制剂诱导胃癌细胞凋亡的机制研究[J].中华肿瘤杂志,2005,27(3):145-147. 被引量:16
  • 4Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer[J].AnnOncol, 1997,8(2):163-168.
  • 5Seidman AD, Oshaughnessy J, Misset JL. Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer[J]. Oncologist, 2002, 17 (6) : 20-28.
  • 6孙燕 周际昌.临床肿瘤内科手册[M].北京:人民卫生出版社,2003.586-591.
  • 7Sorokin A. Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr Pharm Des, 2004,10: 647-657.
  • 8Kaufmann SH, Peereboom D, Buckwalter CA, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst, 1996, 88: 734-741.
  • 9Sweeney CJ. Why cyclooxygenase-2 inhibition plus chemotherapy? Am J Clin Oncol, 2003, 26 : S122-S125.
  • 10Sugiura T, Saikawa Y, Kubota T, et al. Combination chemotherapy with JTE-522, a novel selective cyclooxygenase-2 inhibitor, and cisplatin against gastric cancer cell lines in vitro and in vivo. In Vivo, 2003, 17:229-233.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部